Stammdaten
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Unternehmen & Branche
| Name | ADIAL PHARMACEUTICALS, INC. |
|---|---|
| Ticker | ADIL |
| CIK | 0001513525 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | 00688a205 |
|---|---|
| ISIN | US00688A2050 |
| Typ | Common Stock |
| Marktkapitalisierung | 1,5 Mio. USD |
| Beta | 1,40 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -7,977,171 | -11.93 | 6,673,367 | 5,276,458 | |
| 2025-09-30 | 10-Q | -1,793,651 | -0.08 | 5,659,847 | 4,505,091 | |
| 2025-06-30 | 10-Q | -1,958,556 | -0.18 | 6,801,703 | 5,590,676 | |
| 2025-03-31 | 10-Q | -2,228,801 | -0.34 | 3,451,122 | 2,126,662 | |
| 2024-12-31 | 10-K | -13,197,451 | -68.01 | 5,043,942 | 4,068,084 | |
| 2024-09-30 | 10-Q | -2,191,803 | -0.38 | 6,712,719 | 5,883,673 | |
| 2024-06-30 | 10-Q | -2,458,298 | -0.59 | 4,948,703 | 4,276,821 | |
| 2024-03-31 | 10-Q | -6,476,560 | -2.19 | 6,121,650 | ||
| 2023-12-31 | 10-K | -5,123,341 | -3.60 | 4,736,605 | 4,083,529 | |
| 2023-09-30 | 10-Q | -1,384,976 | -1.18 | 2,867,437 | 2,339,258 | |
| 2023-06-30 | 10-Q | 1,087,804 | 0.96 | 3,778,943 | 3,317,191 | |
| 2023-03-31 | 10-Q | -2,905,836 | -0.11 | 3,901,678 | 1,439,848 | |
| 2022-12-31 | 10-K | -12,731,416 | -12.71 | 5,732,804 | 3,276,494 | |
| 2022-09-30 | 10-Q | -3,109,350 | -3.02 | 7,741,684 | 5,409,045 | |
| 2022-06-30 | 10-Q | -3,847,532 | -3.96 | 10,923,297 | 7,961,380 | |
| 2022-03-31 | 10-Q | -2,907,839 | -0.13 | 13,963,648 | 10,707,325 | |
| 2021-12-31 | 10-K | -19,423,326 | -1.04 | 7,474,975 | 3,507,811 | |
| 2021-09-30 | 10-Q | -4,317,784 | -0.22 | 10,446,206 | 7,200,098 | |
| 2021-06-30 | 10-Q | -4,440,934 | -0.25 | 8,062,915 | 4,829,003 | |
| 2021-03-31 | 10-Q | -4,833,764 | 8,625,499 | 5,617,642 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Hinweis: Keine aktuelleren Daten zu dieser Aktie verfuegbar. Stand der gezeigten 13F-Holdings: 30.09.2024. Letztes global veroeffentlichtes 13F-Quartal: 31.03.2026.
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| 1620 INVESTMENT ADVISORS, INC. | 3,600 | 3,596 | 100.00 |